DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Tobi (Tobramycin Inhalation) - Published Studies

 
 



Tobi Related Published Studies

Well-designed clinical trials related to Tobi (Tobramycin Inhalation)

Higher tobramycin concentration and vibrating mesh technology can shorten antibiotic treatment time in cystic fibrosis. [2011.04]

Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial. [2011.01]

Lung deposition of inhaled tobramycin with eFlow rapid/LC Plus jet nebuliser in healthy and cystic fibrosis subjects. [2011.01]

The use of high resolution computerized tomography (HRCT) of the chest in evaluating the effect of tobramycin solution for inhalation in cystic fibrosis lung disease. [2010.05]

Aerosolization of tobramycin (TOBI) with the PARI LC PLUS reusable nebulizer: which compressor to use? Comparison of the CR60 to the PortaNeb compressor. [2008.09]

A pilot study to compare tobramycin 80 mg injectable preparation with 300 mg solution for inhalation in cystic fibrosis patients. [2008.07]

Novel tobramycin inhalation powder in cystic fibrosis subjects: Pharmacokinetics and safety. [2007.04]

Nebulisers comparison with inhaled tobramycin in young children with cystic fibrosis. [2007.04]

Aerosolized tobramycin in the treatment of ventilator-associated pneumonia: a pilot study. [2007.02]

Clinical Pharmacology Study of Bramitob((R)), a Tobramycin Solution for Nebulization, in Comparison with Tobi((R)). [2007]

A Formulation of Aerosolized Tobramycin (Bramitob((R))) in the Treatment of Patients with Cystic Fibrosis and Pseudomonas aeruginosa Infection : A Double-Blind, Placebo-Controlled, Multicenter Study. [2007]

Efficacy, Safety, and Local Pharmacokinetics of Highly Concentrated Nebulized Tobramycin in Patients with Cystic Fibrosis Colonized with Pseudomonas aeruginosa. [2007]

Well-designed clinical trials possibly related to Tobi (Tobramycin Inhalation)

Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. [2011.09]

Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial. [2010.04]

Inhaled versus systemic antibiotics and airway inflammation in children with cystic fibrosis and Pseudomonas. [2010.03]

Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. [2008.11.01]

Folic acid supplementation inhibits recurrence of colorectal adenomas: A randomized chemoprevention trial. [2008.07.28]

Estimating in vivo airway surface liquid concentration in trials of inhaled antibiotics. [2007.09]

Use of double-blind placebo-controlled N-of-1 trials among stimulant-treated youths in The Netherlands: a descriptive study. [2007.01]

Other research related to Tobi (Tobramycin Inhalation)

[Effect of Inhalation of Tobramycin for 12 Months on Reduction of Hospitalisation Rate in Severe COPD]. [Article in German] [2013]

Inhaled tobramycin effectively reduces FEV1 decline in cystic fibrosis. An instrumental variables analysis. [2013]

Pharmacokinetic and tolerability profiles of tobramycin nebuliser solution 300 mg/4 ml administered by PARI eFlow(®) rapid and PARI LC Plus(®) nebulisers in cystic fibrosis patients. [2013]

Tobramycin for the treatment of bacterial pneumonia in children. [2012]

Fosfomycin/tobramycin for inhalation in patients with cystic fibrosis with pseudomonas airway infection. [2012]

Fosfomycin/Tobramycin for Inhalation in Cystic Fibrosis Patients with Pseudomonas Airway Infection. [2011.11.17]

Disposable versus reusable jet nebulizers for cystic fibrosis treatment with tobramycin. [2011.03]

Outpatient treatment of Pseudomonas aeruginosa bronchial colonization with long-term inhaled colistin, tobramycin, or both in adults without cystic fibrosis. [2011.02]

Adherence with tobramycin inhaled solution and health care utilization. [2011.01.20]

Economic impact of tobramycin in patients with cystic fibrosis in a managed care population. [2011]

Lung deposition of inhaled tobramycin with eFlow rapid/LC Plus jet nebuliser in healthy and cystic fibrosis subjects. [2011]

Colistin-tobramycin combinations are superior to monotherapy concerning the killing of biofilm Pseudomonas aeruginosa. [2010.11.15]

Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: The EVOLVE trial. [2010.10.20]

Lung deposition of inhaled tobramycin with eFlow rapid/LC Plus jet nebuliser in healthy and cystic fibrosis subjects. [2010.09.29]

Budget impact model of tobramycin inhalation solution for treatment of Pseudomonas aeruginosa in cystic fibrosis patients. [2010]

The use of high resolution computerized tomography (HRCT) of the chest in evaluating the effect of tobramycin solution for inhalation in cystic fibrosis lung disease. [2010]

Tobramycin for inhalation in cystic fibrosis: Beyond respiratory improvements. [2009.12]

Evaluation of long-term co-administration of tobramycin and clarithromycin in a mature biofilm model of cystic fibrosis clinical isolates of Pseudomonas aeruginosa. [2009.10]

Antibacterial activities of a fosfomycin/tobramycin combination: a novel inhaled antibiotic for bronchiectasis. [2009.10]

Pharmacokinetics and safety of tobramycin administered by the PARI eFlow rapid nebulizer in cystic fibrosis. [2009.09]

Tobramycin for inhalation in cystic fibrosis: Beyond respiratory improvements. [2009.07.16]

Pulmonary spray dried powders of tobramycin containing sodium stearate to improve aerosolization efficiency. [2009.05]

Inhalation with Tobramycin to improve healing of tracheobronchial reconstruction. [2009.05]

Spray-dried carrier-free dry powder tobramycin formulations with improved dispersion properties. [2009.04]

Physicochemical compatibility of mixtures of dornase alfa and tobramycin containing nebulizer solutions. [2009.02]

Preparation and characterization of spray-dried tobramycin powders containing nanoparticles for pulmonary delivery. [2009.01.05]

Pulmonary deposition of inhaled tobramycin prior to and after respiratory therapy and use of inhaled albuterol in cystic fibrosis patients colonized with Pseudomonas aeruginosa. [2009.01]

Rapid pulmonary delivery of inhaled tobramycin for Pseudomonas infection in cystic fibrosis: a pilot project. [2008.08]

Elevated serum tobramycin concentrations after treatment with tobramycin inhalation in a preterm infant. [2008.07]

Development and validation of HPLC method for the determination of tobramycin in urine samples post-inhalation using pre-column derivatisation with fluorescein isothiocyanate. [2008.06.15]

Pharmacoscintigraphic and pharmacokinetic evaluation of tobramycin DPI formulations in cystic fibrosis patients. [2008.02]

Long-term benefits of inhaled tobramycin in children with cystic fibrosis: first clinical observations from Poland. [2008]

Inhalation of tobramycin in patients with cystic fibrosis: comparison of two methods. [2007.11]

Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis. [2007.07]

Other possibly related research studies

Changes in performance of the Pari eFlow rapid and Pari LC Plus during 6 months use by CF patients. [2009.09]

Octreotide uptake in intracranial metastasis of pancreatic ductal adenocarcinoma origin in a patient with a prolonged clinical course. [2009.01]

Antiretroviral treatment and the health workforce in South Africa: how have ART workers been affected by scaling up? [2008.12]

Cellular effects of long wavelength UV light (UVA) in mammalian cells. [2008.08]

Use of antipsychotic drugs among Dutch youths between 1997 and 2005. [2008.05]

Long-acting methylphenidate-OROS in youths with attention-deficit hyperactivity disorder suboptimally controlled with immediate-release methylphenidate: a study of cost effectiveness in The Netherlands. [2008]

Studying co-medication patterns: the impact of definitions. [2007.04]

Cutaneous allergy testing in patients suspected of an allergic reaction to eye medication. [2009]

Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. [2009.06]

Aerosol antibiotics in cystic fibrosis. [2009.05]

Implementation of European standards of care for cystic fibrosis--control and treatment of infection. [2009.05]

Shifting patterns of inhaled antibiotic use in cystic fibrosis. [2008.09]

Aminoglycoside-induced vestibular injury: maintaining a sense of balance. [2008.09]

Aerosolized antibiotics for non-cystic fibrosis bronchiectasis. [2008.03]

The challenges of quantitative measurement of lung deposition using 99mTc-DTPA from delivery systems with very different delivery times. [2007.09]

Incidence and risk factors for multiple antibiotic-resistant Pseudomonas aeruginosa in cystic fibrosis. [2007.08]

Use of aerosolized aminoglycosides in the treatment of Gram-negative ventilator-associated pneumonia. [2007.06]

The role of aerosolized antimicrobials in the treatment of ventilator-associated pneumonia. [2007.07]

Day care at green care farms: a novel way to stimulate dietary intake of community-dwelling older people with dementia? [2010]

Inhaled anti-infective agents: emphasis on colistin. [2010.04]

Co-morbidity and patterns of care in stimulant-treated children with ADHD in the Netherlands. [2010.02]

DNA methylation differences after exposure to prenatal famine are common and timing- and sex-specific. [2009.11.01]

Current issues around the pharmacotherapy of ADHD in children and adults. [2009.10]

Aztreonam lysine for inhalation solution: in cystic fibrosis. [2010.10.01]

Novel devices for individualized controlled inhalation can optimize aerosol therapy in efficacy, patient care and power of clinical trials. [2009.12.07]

Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. [2009.10.07]

Emerging treatments in cystic fibrosis. [2009.10.01]

Efficacy of aerosol MP-376, a levofloxacin inhalation solution, in models of mouse lung infection due to Pseudomonas aeruginosa. [2009.09]

Development of the first inhaled antibiotic for the treatment of cystic fibrosis. [2010.12.22]

DNA methylation of IGF2, GNASAS, INSIGF and LEP and being born small for gestational age. [2011.02]

External quality assessment for the determination of diphtheria antitoxin in human serum. [2010.08]

Day care at green care farms: a novel way to stimulate dietary intake of community-dwelling older people with dementia? [2010.05]

The impact of ART scale upon health workers: evidence from two South African districts. [2010]

Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis. [2011.04.04]

Inhaled antibiotics for long-term therapy in cystic fibrosis. [2011.03.16]

Levofloxacin reduces inflammatory cytokine levels in human bronchial epithelia cells: implications for aerosol MP-376 (levofloxacin solution for inhalation) treatment of chronic pulmonary infections. [2011.03]

Improving evidence-based care in cystic fibrosis through quality improvement. [2010.10]

In vitro inhibition of neutrophil elastase activity by inhaled anti-Pseudomonas antibiotics used in cystic fibrosis patients. [2010]

Inhaled anti-infective agents: emphasis on colistin. [2010]

Early antibiotic treatment for Pseudomonas aeruginosa eradication in patients with cystic fibrosis: a randomised multicentre study comparing two different protocols. [2012]

Therapeutic approaches to chronic cystic fibrosis respiratory infections with available, emerging aerosolized antibiotics. [2011]

Inhaled antibiotics for long-term therapy in cystic fibrosis. [2011]

Inhaled versus systemic antibiotics and airway inflammation in children with cystic fibrosis and Pseudomonas. [2010]

Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial. [2010]

The effects of dexamethasone and metoclopramide on early and late postoperative nausea and vomiting in women undergoing myomectomy under spinal anaesthesia. [2014]

The cost effectiveness of dry powder antibiotics for the treatment of Pseudomonas aeruginosa in patients with cystic fibrosis. [2014]

Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. [2014]

Inhaled antibiotics for stable non-cystic fibrosis bronchiectasis: a systematic review. [2014]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017